The MEU is a UK leader in First in Man studies. We have considerable expertise in SAD and MAD trials. The emergence of hybrid designs, including patient cohorts, has allowed the MEU to provide a complete solution for clients seeking a single site solution for their Phase 1 programme.
The MEU is well-equipped to undertake large single centre early phase healthy volunteer clinical trials and specialist respiratory trials including Asthma, COPD, Cystic Fibrosis, Allergy, Dermatology, Inflammatory, Cardiovascular and Diabetes. Our ever-expansive portfolio facilitates the MEU to undertake Phase 1 studies in many other therapeutic areas.
State-of-the-art, hospital-based facilities including 36 inpatient beds with cardiac and telemetry monitoring, a pharmacy, clinical assessment suite, bronchoscopy unit and numerous outpatient/consultant rooms.
Contact us today to sense-check your protocol synopsis against our ICARUS phenotyped database of over 17,000 clinical trial volunteers. We can run inclusion/exclusion criteria in minutes, instantly checking the phenotyped data across multiple therapeutic fields.
The MEU is an MHRA Phase 1 accredited unit and has been part of the scheme since its inception. This ensures that our studies are conducted to the highest standards in terms of both safety and quality.
MEU have held MHRA Phase 1 accreditation since July 2009 with the latest inspection being 2018
Our last five inspections, shown below, show 10 Years of No Criticals and, No Majors findings:
The initiation of the Phase 2 study in patients in the United Kingdom (UK) follows the successful completion of dosing in the Phase 1 study in healthy volunteers at the same clinical unit in the UK, allowing for a rapid transition to Phase 2.
During these challenging times, it’s important to celebrate good news and we are delighted to announce today that we have been honoured with The Queen’s Award for Enterprise in International Trade! The awards have been announced today, on Her Majesty The Queen’s 94th birthday, and The MEU is one of the 220 organisations nationally to […]
We’re looking forward to attending The 3rd Cystic Fibrosis Clinical Trials Meeting: Improving Access for All in Nottingham later this month. The event proposes a number of highly regarded UK and international speakers, and has been developed by the scientific committee to cover a broad range of stakeholders and to respond to the needs of […]
© 2020 Medicines Evaluation Unit · All rights reserved · Email Login